Table 1 |
|||||||
|
Effect of huRANKL treatment of C4-2 cells on bone morphometry |
|||||||
|
BV/TV (%) |
TuV/TV (%) |
Tb.Th. (μm) |
Tb.N. (mm-1) |
Tb.Sp. (μm) |
Ob.Pm./B.Pm. (%) |
N.Oc./BS (#/mm) |
|
|
|
|||||||
|
Control |
5.88 ± 0.99 |
80.48 ± 2.49 |
31.58 ± 4.83 |
2.03 ± 0.42 |
597.24 ± 215.70 |
5.23 ± 1.03 |
4.06 ± 0.37 |
|
Prevention |
6.65 ± 2.31 |
78.69 ± 2.06 |
34.27 ± 2.05 |
1.84 ± 0.50 |
690.77 ± 188.80 |
9.51 ± 1.76a |
4.37 ± 0.71 |
|
Treatment |
6.75 ± 1.72 |
77.85 ± 2.99 |
36.00 ± 4.80 |
1.79 ± 0.37 |
633.46 ± 193.00 |
8.35 ± 2.66 |
6.32 ± 0.50b |
|
|
|||||||
|
Bone histomorphometric analysis was performed in the area adjacent to the growth plate (0.525–1.225 mm below the growth plate: site of injection, n = 4 in control and treatment animals; n = 5 in prevention animals. Two animals were removed from the analysis due to sectioning difficulties. Results are expressed as mean ± SE. Statistical significance was evaluated using student's paired t test. a Control vs. prevention (p < 0.05). b Control vs. treatment (p < 0.05). Abbreviations: %BV/TV, percentage bone volume in tissue volume; %TuV/TV, tumor volume in tissue volume as a percentage; Tb.Th., trabecular thickness in μm; Tb.N., trabecular number per mm; Tb.Sp., trabecular seperation in μm; Ob.Pm./B.Pm., osteoblast perimeter to bone perimeter; N.Oc./BS, ratio of osteoclast number to bone surface. |
|||||||
|
Morrissey et al. BMC Cancer 2007 7:148 doi:10.1186/1471-2407-7-148 |
|||||||
